The cancer diagnostics company has gone into a trading halt following an adverse decision on reimbursement of its US bladder tests.
The beleaguered glass supplier has implemented leadership change and cost-cuts but outlook remains ‘soft’.
Those wanting an update on the sale of the consumer businesses were told to wait until something happened, as the dairy giant updated its full year forecast.
However, ‘process failings’ were identified in the judgment.
‘For the longest time it felt like we were a lone voice and there were plenty of detractors,’ says chair Stiassny on the insurer’s risk-based pricing.
Group also follows retirement sector lead in scrapping dividend while it ponders restructuring options.
Travel management software provider responds to ForBarr's 'underperform' rating.
Palestine supporters have asked the NZX-listed company to stop supplying its tech to weapons manufacturers.
Listed retirement village operator says chronic underfunding will result in a wider public 'healthcare problem' as retirement sector becomes unprofitable.
Dual-listed fintech's revenue grew 24% in FY24 as it enters the NZ market as an 'acquirer' in FY25.